Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients
aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with
severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to
intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
2 Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic
Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see
section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).
How to take it
The way to take this medicine is: Subcutaneous.
This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Protect from Light
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to opalescent, colourless to pale yellow to pale brown solution in a pre-filled syringe.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients
aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with
severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to
intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
2 Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic
Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see
section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).
How to take it
The way to take this medicine is: Subcutaneous.
This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Protect from Light
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to opalescent, colourless to pale yellow to pale brown solution in a pre-filled pen.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients
aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with
severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to
intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical
2 Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic
Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see
section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).
How to take it
The way to take this medicine is: Subcutaneous.
This medicine is injected, usually with a short needle or pen-like device, into the fat just beneath the skin.
Store below 25 degrees Celsius
Do not Freeze
Shelf lifetime is 48 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Lyophilised powder in 10 mL type I glass vial with bromobutyl rubber (non-latex) stopper and a gray aluminium overseal with a plastic flip-cap.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.